Editorial

Published on 11 May 2015

Editorial: Multidrug Resistance in Cancer: Pharmacological Strategies from Basic Research to Clinical Issues

in Pharmacology of Anti-Cancer Drugs

Chiara Riganti
Enrico Mini
Stefania Nobili

Frontiers in Oncology

doi 10.3389/fonc.2015.00105

4,717 views
21 citations

Original Research

Published on 11 May 2015

Pazopanib-Induced Alopecia, an Underestimated Toxicity?

in Pharmacology of Anti-Cancer Drugs

Andrea Biondo
Helen Alexander
Komel Khabra
Lisa Pickering
Martin Gore
James Larkin

Frontiers in Oncology

doi 10.3389/fonc.2015.00112

4,355 views
5 citations

Original Research

Published on 15 Aug 2014

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer

in Pharmacology of Anti-Cancer Drugs

Boye Schnack Nielsen
Eva Balslev
Tim Svenstrup Poulsen
Dorte Nielsen
Trine Møller
Christiane Ehlers Mortensen
Kim Holmstrøm
Estrid Høgdall

Frontiers in Oncology

doi 10.3389/fonc.2014.00207

7,147 views
23 citations

Editorial

Published on 04 Aug 2014

Drug-Diagnostics Co-Development in Oncology

in Pharmacology of Anti-Cancer Drugs

Jan Trøst Jørgensen

Frontiers in Oncology

doi 10.3389/fonc.2014.00208

7,441 views
5 citations

Clinical Case Study

Published on 24 Jul 2014

A Case of Retinal Tear Associated with Use of Sorafenib

in Pharmacology of Anti-Cancer Drugs

Kelly M. Gaertner
Stephen H. Caldwell
Osama E. Rahma

Frontiers in Oncology

doi 10.3389/fonc.2014.00196

3,955 views
8 citations

Review

Published on 13 Jun 2014

Co-Development of Diagnostic Vectors to Support Targeted Therapies and Theranostics: Essential Tools in Personalized Cancer Therapy

in Pharmacology of Anti-Cancer Drugs

Nicholas C. Nicolaides
Daniel J. O’Shannessy
Earl Albone
Luigi Grasso

Frontiers in Oncology

doi 10.3389/fonc.2014.00141

11,542 views
27 citations

Review

Published on 16 May 2014

Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects

in Pharmacology of Anti-Cancer Drugs

Dana Olsen
Jan Trøst Jørgensen

Frontiers in Oncology

doi 10.3389/fonc.2014.00105

42,390 views
80 citations

Review

Published on 17 Apr 2014

Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics

in Pharmacology of Anti-Cancer Drugs

Saumya Pant
Russell Weiner
Matthew J. Marton

Frontiers in Oncology

doi 10.3389/fonc.2014.00078

41,841 views
77 citations

Review

Published on 01 Apr 2014

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

in Pharmacology of Anti-Cancer Drugs

Sai-Hong Ignatius Ou

Frontiers in Oncology

doi 10.3389/fonc.2014.00058

13,411 views
24 citations

Methods

Published on 06 Mar 2014

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies

in Pharmacology of Anti-Cancer Drugs

Martina McDermott
Alex Eustace
Steven Busschots
Laura Breen
Martin Clynes
Norma O'Donovan
Britta Stordal

Frontiers in Oncology

doi 10.3389/fonc.2014.00040

75,875 views
233 citations

Review

Published on 03 Mar 2014

Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function

in Pharmacology of Anti-Cancer Drugs

Frances Jane Sharom

Frontiers in Oncology

doi 10.3389/fonc.2014.00041

21,512 views
228 citations

Original Research

Published on 05 Feb 2014

Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations

in Pharmacology of Anti-Cancer Drugs

Alexey Goltsov
Simon Langdon
Gregory Goltsov
David Harrison
James Bown

Frontiers in Oncology

doi 10.3389/fonc.2014.00013

7,142 views
14 citations

Review

Published on 21 Jan 2014

Small and Innovative Molecules as New Strategy to Revert MDR

in Pharmacology of Anti-Cancer Drugs

Laura Zinzi
Elena Capparelli
Mariangela Cantore
Marialessandra Contino
Marcello Leopoldo
Nicola Antonio Colabufo

Frontiers in Oncology

doi 10.3389/fonc.2014.00002

9,677 views
73 citations

Mini Review

Published on 30 Dec 2013

Where is it and How Does it Get There – Intracellular Localization and Traffic of P-glycoprotein

in Pharmacology of Anti-Cancer Drugs

Dong Fu

Frontiers in Oncology

doi 10.3389/fonc.2013.00321

9,989 views
54 citations

Hypothesis and Theory

Published on 27 Dec 2013

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling

in Pharmacology of Anti-Cancer Drugs

Annika Bettina Foehrenbacher
Timothy W. Secomb
William R. Wilson
Kevin O Hicks

Frontiers in Oncology

doi 10.3389/fonc.2013.00314

9,036 views
37 citations

Review

Published on 25 Dec 2013

Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development

in Pharmacology of Anti-Cancer Drugs

Jan Stenvang
Iben Kümler
Sune Boris Nygård
David Hersey Smith
Dorte Nielsen
Nils Brünner
Jose Manuel Afonso Moreira

Frontiers in Oncology

doi 10.3389/fonc.2013.00313

13,567 views
43 citations

Navigation group

Articles

Editorial: Multidrug Resistance in Cancer: Pharmacological Strategies from Basic Research to Clinical Issues

Pazopanib-Induced Alopecia, an Underestimated Toxicity?

miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer

Drug-Diagnostics Co-Development in Oncology

A Case of Retinal Tear Associated with Use of Sorafenib

Co-Development of Diagnostic Vectors to Support Targeted Therapies and Theranostics: Essential Tools in Personalized Cancer Therapy

Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects

Navigating the Rapids: The Development of Regulated Next-Generation Sequencing-Based Clinical Trial Assays and Companion Diagnostics

Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies

Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function

Customizing the Therapeutic Response of Signaling Networks to Promote Antitumor Responses by Drug Combinations

Small and Innovative Molecules as New Strategy to Revert MDR

Where is it and How Does it Get There – Intracellular Localization and Traffic of P-glycoprotein

Design of Optimized Hypoxia-Activated Prodrugs Using Pharmacokinetic/Pharmacodynamic Modeling

Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development